Current status of bare and drug-eluting stents in infrainguinal peripheral vascular disease

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 4, 2008, Pages 531-538

  Schmehl, Jörg ^a   Tepe, Gunnar ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Drug elution; Everolimus; Infragenicular angioplasty; Nitinol; Paclitaxel; Sirolimus; Superficial femoral artery

Indexed keywords

DACRON; EVEROLIMUS; NITINOL; PACLITAXEL; POLITEF; RAPAMYCIN;

BARE ELUTING STENT; CLINICAL TRIAL; DRUG ABSORPTION; DRUG COATING; DRUG ELUTING STENT; DRUG MECHANISM; ENDOVASCULAR SURGERY; EXERCISE; HUMAN; IN-STENT RESTENOSIS; INGUINAL REGION; LIFESTYLE MODIFICATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POPLITEAL ARTERY; REVIEW; STENT; SUPERFICIAL FEMORAL ARTERY; EQUIPMENT; FEMORAL ARTERY; LEG; PATHOLOGY; PATIENT SELECTION; VASCULARIZATION;

DRUG-ELUTING STENTS; EQUIPMENT FAILURE; FEMORAL ARTERY; HUMANS; LEG; PATIENT SELECTION; PERIPHERAL VASCULAR DISEASES; STENTS;

EID: 43049176721     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.4.531     Document Type: Review

References (42)

1. White JV, Ryjewski C. Progress in the endovascular treatment of intermittent claudication: rationale for changes in the TASC classification. Semin. Vasc. Surg. 20(1), 54-61 (2007).
2. Grenacher I, Saam T, Geier A et al. PTA versus Palmaz stent placement in femoropopliteal artery stenoses: results of a multicenter prospective randomized study (REFSA). Rofo. 176(9), 1302-1310 (2004).
3. Grimm J, Muller-Hulsbeck S, Jahnke T, Hilbert C, Brossmann J, Heller M. Randomized study to compare PTA alone versus PTA with Palmaz stent placement for femoropopliteal lesions. J. Vasc. Interv. Radiol. 12(8), 935-942 (2001).
4. Cejna M, Thurnher S, Illiasch H et al. PTA versus Palmaz stent placement in femoropopliteal artery obstructions: a multicenter prospective randomized study. J. Vasc. Interv. Radiol. 12(1), 23-31 (2001).
5. Gordon IL, Conroy RM, Arefi M, Tobis JM, Stemmer EA, Wilson SE. Three-year outcome of endovascular treatment of superficial femoral artery occlusion. Arch. Surg. 136(2), 221-228 (2001).
6. Mewissen MW. Self-expanding nitinol stents in the femoropopliteal segment: technique and mid-term results. Tech. Vasc. Interv. Radiol. 7(1), 2-5 (2004).
7. Krankenberg H, Schluter M, Steinkamp HJ et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 116(3), 285-292 (2007).
8. Schillinger M, Sabeti S, Loewe C et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N. Engl. J. Med. 354(18), 1879-1888 (2006).
9. Sabeti S, Mlekusch W, Amighi J, Minar E, Schillinger M. Primary patency of long-segment self-expanding nitinol stents in the femoropopliteal arteries. J. Endovasc. Ther. 12(1), 6-12 (2005).
10. Scheinert D, Scheinert S, Sax J et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J. Am. Coll. Cardiol. 45(2), 312-315 (2005).
11. Schlager O, Dick P, Sabeti S et al. Long-segment SFA stenting - the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J. Endovasc. Ther. 12(6), 676-684 (2005).
12. Jaff M, Dake M, Pompa J, Ansel G, Yoder T. Standardized evaluation and reporting of stent fractures in clinical trials of noncoronary devices. Catheter Cardiovasc. Intern 70(3), 460-462 (2007).
13. Schillinger M, Sabeti S, Dick P et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 115(21), 2745-2749 (2007).
14. Duda SH, Bosiers M, Lammer J et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J. Endovasc. Ther. 13(6), 701-710 (2006).
15. Ahmadi R, Schillinger M, Maca T, Minar E. Femoropopliteal arteries: immediate and tong-term results with a Dacron-covered stent-graft. Radiology 223(2), 345-350 (2002).
16. Saxon RR, Coffman JM, Gooding JM, Natuzzi E, Ponec DJ. Long-term results of ePTFE stent-graft versus angioplasty in the femoropopliteal artery: single center experience from a prospective, randomized trial. J Vasc. Interv. Radiol. 14(3), 303-311 (2003).
17. Wiesinger B, Beregi JP. Oliva VL et al. PTFE-covered self-expanding nitinol stents for the treatment of severe iliac and femoral artery stenoses and occlusions: final results from a prospective study. J. Endovasc. Ther. 12(2), 240-246 (2005).
18. Kedora J, Hohmann S, Garrett W, Munschaur C, Theune B, Gable D. Randomized comparison of percutaneous Viabahn stent grafts vs prosthetic femoral - popliteal bypass in the treatment of superficial femoral arterial occlusive disease. J. Vasc. Surg. 45(1), 10-16 (2007).
19. Fischer M, Schwabe C, Schulte KL. Value of the hemobahn/viabahn endoprosthesis in the treatment of long chronic lesions of the superficial femoral artery: 6 years of experience. J. Endovasc. Ther. 13(3), 281-290 (2006).
20. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation 107(17), 2274-2279 (2003).
21. Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 107(1), 38-42 (2003).
22. Gallo R, Padurean A, Jayaraman T et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 99(16), 2164-2170 (1999).
23. Sousa JE, Costa MA, Abizaid AC et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104(17), 2007-2011 (2001).
24. Sousa JE, Costa MA, Abizaid A et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirotimus-eluting stents. Circulation 111(18), 2326-2329 (2005).
25. Tsuchiya Y, Lansky AJ, Costa RA et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am. J. Cardiol. 98(4), 464-469 (2006).
26. Duda SH, Bosiers M, Lammer J et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J. Vasc. Interv. Radiol. 16(3), 331-338 (2005).
27. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) - summary of recommendations. J. Visc. Interv. Radiol. 17(9), 1383-1397 (2006).
28. Feiring AJ, Wesolowski AA, Lade S. Primary stent-supported angioplasty for treatment of below-knee critical limb ischemia and severe claudication: early and one-year outcomes. J. Am. Coll. Caradiol. 44(12), 2307-2314 (2004).
29. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation 104(17), 2057-2062 (2001).
30. Krankenberg H, Sorge I, Zeller T, Tubler T. Percutaneous transluminal angioplasty of infrapopliteal arteries in patients with intermittent claudication: acute and one-year results. Catheter. Cardiovasc. Interv. 64(1), 12-17 (2005).
31. Balmer H, Mahler F, Do DD, Triller J, Baumgartner I. Balloon angioplasty in chronic critical limb ischemia: factors affecting clinical and angiographic outcome. J. Endovasc. Ther. 9(4), 403-410 (2002).
32. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular therapy as the primary approach for limb salvage in patients with critical limb ischemia: experience with 443 infrapopliteal procedures. Vascular 14(2), 63-69 (2006).
33. Tepe G, Zeller T, Heller S et al. Self-expanding nitinol stents for treatment of infragenicular arteries following unsuccessful balloon angioplasty. Eur. Radiol. 17(8), 2088-2095 (2007).
34. Kickuth R, Keo HH, Triller J, Ludwig K, Do DD. Initial clinical experience with the 4-F self-expanding XPERT stent system for infrapopliteal treatment of patients with severe claudication and critical limb ischemia. J. Vasc. Interv. Radiol. 18(6), 703-708 (2007).
35. Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Karsanos K, Tsolakis J. Sirolimus-eluting versus bare stents for bailout after suboptimal infrapopliteal angioplasty for critical limb ischemia: 6-month angiographic results from a nonrandomized prospective single-center study. J. Endovasc. Ther. 12(6), 685-695 (2005).
36. Siablis D, Karnabatidis D, Katsanos K et al. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit. J. Endovasc. Ther. 14(2), 241-250 (2007).
37. Commeau P, Barragan P, Roquebert PO. Sirolimus for below-the-knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc. Interv. 68(5), 793-798 (2006).
38. Bosiers M, Deloose K, Verbist J, Peeters P. Percutaneous transluminal angioplasty for treatment of 'below-the-knee' critical limb ischemia: early outcomes following the use of sirolimus-eluting stents. J. Cardiovasc. Surg. (Torino). 47(2), 171-176 (2006).
39. Scheller B, Hehrlein C, Bocksch W et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N. Engl. J. Med. 355(20), 2113-2124 (2006).
40. Peeters P, Bosiers M, Verbist J, Deloose K, Heublein B. Preliminary results after application of absorbable metal stents in patients with critical limb ischemia. J. Endovasc. Ther. 12(1), 1-5 (2005).
41. Ormiston JA, Webster MW, Armstrong G. First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. Catheter Cardiovasc. Interv. 69(1), 128-131 (2007).
42. Etbel R, Di Mario C, Bartunek J et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 369(9576), 1869-1875 (2007).